Actively Recruiting
Evaluating RNA Editing to Predict Response to Vortioxetine and Cariprazine in Adults with Unipolar and Bipolar Depression
Led by Mayo Clinic · Updated on 2026-06-22
120
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how changes in RNA editing relate to treatment response in adults with unipolar and bipolar depression. This trial aims to evaluate antidepressant response using medication in adults aged 18 to 65 who have current major depressive episodes associated with major depressive disorder or bipolar disorder. The study is focused on understanding the relationship between RNA editing and symptom improvement during treatment. Participants will start treatment with vortioxetine taken once daily for 8 weeks, beginning at 10 mg per day and increasing to 20 mg per day after the first week. If participants do not reach remission after this period, they will enter an 8-week augmentation phase where cariprazine is added to their regimen, starting at 1.5 mg per day and increasing to 3.0 mg per day. This two-phase drug treatment approach is designed to monitor response to antidepressants over 16 weeks. During the study, participants will attend assessment visits at baseline, week 2, week 8, week 10, and week 16. Researchers will measure changes in depression severity using the Montgomery-sberg Depression Rating Scale MADRS and monitor treatment response closely. Safety and treatment adherence will also be tracked. The total study duration for each participant is up to 16 weeks, with primary outcome measures focused on changes in depressive symptoms over this period.
CONDITIONS
Brief Title
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
Research Team
S
Scott E. Feeder
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here